Tofacitinib (7) (Xeljanz®) – Ankylosing spondylitis (AS)

Characteristics

Start date 15.12.2021
Resolution 16.06.2022
INN Tofacitinib
Brand name Xeljanz®
Pharm. company Pfizer Pharma GmbH
G-BA procedure ID 2021-12-15-D-764
Therapeutic area Musculoskeletal system diseases
Reason for procedure New Indication

Indication (German)

Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy

Subpopulation Indication Comparator
a1) Adults with active ankylosing spondylitis (AS) who have had an inadequate response to conventional therapy and who are eligible for treatment with tofacitinib. A TNF-α inhibitor (adalimumab or certolizumab pegol or etanercept or golimumab or infliximab) or an IL17 inhibitor (secukinumab).
a2) Adults with active ankylosing spondylitis (AS)who have responded inadequately to previous therapy with biological with biologic antirheumatic drugs (bDMARDs) or who are intolerant to these drugs and who are or who are intolerant to them and who are eligible for treatment with tofacitinib. Switching to another biological disease-modifying antirheumatic drug: TNF-α inhibitor (adalimumab or certolizumab pegol or etanercept or golimumab or infliximab) or IL17 inhibitor (secukinumab).

9. Associated procedures



<< List of all resolutions